

January 23, 2026

To,
Listing Department,
The BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400001.

Scrip Code: 540737

Dear Sir(s)/Ma'am,

Sub: Press Release

With reference to the captioned subject, we enclose herewith the Press Release with respect to Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2025.

Kindly take the same on your record.

Thanking You,

Yours faithfully,

For Shree Ganesh Remedies Limited

Aditya Patel
Company Secretary and Compliance Officer

Enc. a/a



Head Office :
Plot No. 6011, 6012, 6002 & 6003,
GIDC Estate, Ankleshwar - 393 002,
Gujarat (INDIA)
Ph.: +91 9614961469, 7574976076
CIN No.: L24230GJ1995PLC025661

(Unit-2) :
Plot No. 6714/2,-6715 GIDC Estate,
Ankleshwar - 393 002, Gujarat (INDIA)
Ph.: +91 9614961469, 7574976076
GSTIN : 24ABACS1471R1ZD (Zero)



www.ganeshremedies.com
WEBSITE
contact@ganeshremedies.com
EMAIL

SHREE GANESH REMEDIES LIMITED REPORTS Q3 & 9MFY26 RESULTS

Ankleshwar, January 23rd, 2026: Shree Ganesh Remedies Limited, one of the fastest growing CMO & CDMO based in India for Pharmaceutical Intermediates & Fine Chemicals, announced its financial results for Q3 & 9MFY26.

Commenting on the results, Mr. Gunjan Kothia, Promoter, Head of Business Development & Innovation, said:

"Q3FY26 was impacted by three key factors. First, we witnessed delays in shipments due to the Christmas holiday period across select key client accounts. This has deferred revenue recognition and is expected to shift into Q4FY26. The quantum of deferment is estimated at around 10-12% of the reported topline for the quarter. Second, the demand environment in Europe remained challenging, leading to lower sales. Third, we saw heightened competitive intensity across parts of our product portfolio, resulting in price-led competition and lower realisations. Collectively, these factors contributed to the decline in topline during the quarter.

Despite this near-term pressure, our long-term outlook remains intact. As communicated earlier, FY26 is a year of consolidation, and we continue to prioritise execution and capability-building over aggressive growth. The team remains focused on driving volume improvement to offset softer realisations and sustain sales performance at levels comparable to the previous year.

Operationally, progress remains steady. Our new pilot facility is now commissioned and operational, strengthening our ability to accelerate product development and improve responsiveness to customer requirements. Our expansion programme for Block 7 is progressing as planned, with commercial production expected to commence in H1FY27. The CRAMS engagement with our Japanese client also continues to advance positively in line with the project roadmap.

Looking ahead to FY27, we expect a gradual improvement in business momentum. With the pilot facility fully active, we have increased the pace of new product development to broaden our portfolio and address pressures from competition and realisation trends. We expect the CRAMS business to gain traction during FY27, supported by ongoing project execution and customer engagement. Overall, we remain focused on disciplined growth, strengthening our platform for scale-up, and delivering sustainable profitability through the cycle."

Financial Highlights for Quarter Ended December 31st, 2025:

(₹ In crore & %)

REVENUE	EBITDA
21.11 Cr.	6.73 Cr.
₹ -22% YoY	₹ -32% YoY
PAT	EBITDA MARGINS
3.10 Cr.	31.9 %
₹ -43% YoY	₹ -471 BPS YoY
15.74 Cr.	5.37 Cr.*
Revenue from Pharma Intermediates in Q3FY26	Revenue from Speciality Chemicals in Q3FY26
9.24 Cr.	11.87 Cr.*
Revenue from Exports in Q3FY26	Revenue from Domestic Sales in Q3FY26

Financial Highlights for 9 Month Ended December 31st, 2025:

(₹ In crore & %)

REVENUE	EBITDA
76.09 Cr.	23.65 Cr.
₹ -10% YoY	₹ -19% YoY
PAT	EBITDA MARGINS
11.50 Cr.	31.1 %
₹ -30% YoY	₹ -378 BPS YoY
48.37 Cr.	27.72 Cr.*
Revenue from Pharma Intermediates in 9MFY26	Revenue from Speciality Chemicals in 9MFY26
37.96 Cr.	38.13 Cr.*
Revenue from Exports in 9MFY26	Revenue from Domestic Sales in 9MFY26

*Revenue excluding other operating income

Financial Highlights:

PARTICULARS (₹ IN CRORES)	Q3FY25	Q2FY26	Q3FY26	YoY Change	QoQ Change	9MFY25	9MFY26	YoY Change
Revenue from Operations	27.05	30.32	21.11	-22%	-30%	84.16	76.09	-10%
Total Income	27.76	31.00	21.76	-22%	30%	85.61	78.10	-9%
Operating Expenses	17.15	20.70	14.38	-16%	-31%	54.83	52.44	-4%
EBITDA (Excluding OI & EI)	9.90	9.62	6.73	-32%	-30%	29.33	23.65	-19%
EBITDA %	36.6%	31.7%	31.9%	-471 bps	16 bps	34.9%	31.1%	-378 bps
Finance Cost	0.38	1.01	0.74	96%	-27%	1.12	2.69	140%
Depreciation & Ammortization	2.70	2.59	2.67	-1%	3%	7.14	7.67	7%
PBT	7.54	6.71	3.98	-47%	-41%	22.52	15.29	-32%
PAT	5.43	4.96	3.10	-43%	-38%	16.50	11.50	-30%
EPS (₹)	4.23	3.86	2.41	-43%	-38%	12.85	8.96	-30%

About Shree Ganesh Remedies Limited: (SGRL)

Shree Ganesh Remedies Limited is a leading player in the chemical manufacturing industry, specialising in pharmaceutical intermediates and specialty chemicals. With over 19 years of excellence, the company is renowned for its unparalleled expertise in advanced chemical synthesis and complex chemical reactions. Strategically expanding its operations, Shree Ganesh Remedies is focused on innovation through strategic R&D investments and state-of-the-art infrastructure. The company serves over 20 countries, including key markets in the EU and the US, offering tailored solutions to global industry leaders. Committed to sustainable practices, Shree Ganesh Remedies holds multiple accreditations, including ISO certifications and EcoVadis Bronze. With ongoing expansions at its Ankleshwar and Dahej sites and a strategic shift towards complex niche specialty chemicals, the company is well-positioned for future growth and continues to deliver high-quality, custom manufacturing solutions to its clients.

Contact us:

Aditya Patel

Company Secretary

Shree Ganesh Remedies Limited

Email: investors@ganeshremedies.com

Abhishek Mehra

Investor Relations Advisors

TIL Advisors Private Limited

Email: abhishek@theinvestmentlab.in

Mobile No.: +91 95588 14500

Certain statements in this document that are not historical facts are forward looking statements. Such forward looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward- looking statements. Shree Ganesh Remedies Limited will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.